The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Intravenous Glucocorticoids for Graves' Orbitopathy: Efficacy and Morbidity
Abstract
CONTEXT: The administration of iv glucocorticoid pulses has been advocated as a treatment approach for patients with inflammatory and moderate to severe Graves' orbitopathy (GO). This review offers an update on this controversial regimen. EVIDENCE ACQUISITION: PubMed and the MeSH-Database were searched (with no temporal limit) for the following topics: management of active and severe GO; glucocorticoid therapy of GO; iv glucocorticoid administration; mechanism and pharmacokinetics of iv glucocorticoids; and adverse events, morbidity, and mortality of iv glucocorticoids. The articles were evaluated according to their setting and study design. EVIDENCE SYNTHESIS: All randomized and uncontrolled trials, consensus statement, systematic reviews, and meta-analyses dealing with the efficacy and morbidity of iv glucocorticoids in GO were identified. CONCLUSIONS: The current first-line treatment for active, moderate-to-severe GO is a 12-wk course of high-dose iv glucocorticoid pulses. The response rate of this regimen is approximately 80%. Intravenous glucocorticoids have a statistically significant advantage over oral treatment and cause significantly fewer adverse events. However, major side effects related to preexisting diseases, administered dose, and treatment schedule have been reported. The morbidity and mortality of iv glucocorticoid therapy are 6.5 and 0.6%, respectively. Thus, careful patient selection is warranted. Before iv glucocorticoid administration, patients should be screened for recent hepatitis, liver dysfunction, cardiovascular morbidity, severe hypertension, inadequately managed diabetes, and glaucoma. The cumulative dose should not exceed 8 g, and with the exception of sight-threatening GO the single doses preferably should not be administered on consecutive days. Monthly monitoring during subsequent treatment is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO
Bartalena, L., Baldeschi, L., Dickinson, A., Eckstein, A., Kendall-Taylor, P., Marcocci, C., Mourits, M., Perros, P., Boboridis, K., Boschi, A., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0666 · Cited by 795
Self-citationMourits, M. P., Koornneef, L., Wiersinga, W. M., Prummel, M. F., Berghout, A., & van der Gaag, R. (1989) · British Journal of Ophthalmology · doi:10.1136/bjo.73.8.639 · Cited by 721
Brent, G. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmcp0801880 · Cited by 594
Randomized, Single Blind Trial of Intravenous versus Oral Steroid Monotherapy in Graves’ Orbitopathy
Kahaly, G. J., Pitz, S., Hommel, G., & Dittmar, M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0148 · Cited by 423
Self-citationBartalena, L., Baldeschi, L., Dickinson, A. J., Eckstein, A., Kendall-Taylor, P., Marcocci, C., Mourits, M. P., Perros, P., Boboridis, K., Boschi, A., et al. (2008) · Thyroid · doi:10.1089/thy.2007.0315 · Cited by 406
Self-citationBartalena, L., & Tanda, M. L. (2009) · New England Journal of Medicine · doi:10.1056/nejmcp0806317 · Cited by 336
Randomised double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy
Prummel, M. F., Berghout, A., Wiersinga, W. M., Mourits, M. P., Koornneef, L., & Blank, L. (1993) · The Lancet · doi:10.1016/0140-6736(93)92001-a · Cited by 332
Bartalena, L., Marcocci, C., Bogazzi, F., Panicucci, M., Lepri, A., & Pinchera, A. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212001 · Cited by 318
Marcocci, C. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.8.3562 · Cited by 309
Cigarette Smoking and Treatment Outcomes in Graves Ophthalmopathy
Bartalena, L., Marcocci, C., Tanda, M. L., Manetti, L., Dell'Unto, E., Bartolomei, M. P., Nardi, M., Martino, E., & Pinchera, A. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-8-199810150-00010 · Cited by 295
Ikappa Balpha -independent downregulation of NF-kappa B activity by glucocorticoid receptor
Heck, S. (1997) · The EMBO Journal · doi:10.1093/emboj/16.15.4698 · Cited by 295
Modification of the Classification of the Eye Changes of Graves' Disease
Werner, S. C. (1977) · American Journal of Ophthalmology · doi:10.1016/0002-9394(77)90140-4 · Cited by 282
Buttgereit, F., Wehling, M., & Burmester, G.-R. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199805)41:5<761::aid-art2>3.0.co;2-m · Cited by 226
Wakelkamp, I. M. M. J., Baldeschi, L., Saeed, P., Mourits, M. P., Prummel, M. F., & Wiersinga, W. M. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02345.x · Cited by 217
Treatment Modalities for Graves’ Ophthalmopathy: Systematic Review and Metaanalysis
Stiebel-Kalish, H., Robenshtok, E., Hasanreisoglu, M., Ezrachi, D., Shimon, I., & Leibovici, L. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0376 · Cited by 213
Lindenauer, P. K. (2010) · JAMA · doi:10.1001/jama.2010.796 · Cited by 196
Psychosocial morbidity of Graves’ orbitopathy
Kahaly, G. J., Petrak, F., Hardt, J., Pitz, S., & Egle, U. T. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02352.x · Cited by 184
Self-citationMarinò, M., Morabito, E., Brunetto, M. R., Bartalena, L., Pinchera, A., & Marocci, C. (2004) · Thyroid · doi:10.1089/105072504774193276 · Cited by 170
Adverse Effects of Corticosteroid Therapy for COPD
McEvoy, C. E., & Niewoehner, D. E. (1997) · Chest · doi:10.1378/chest.111.3.732 · Cited by 160
Oral or IV Prednisolone in the Treatment of COPD Exacerbations
de Jong, Y. P., Uil, S. M., Grotjohan, H. P., Postma, D. S., Kerstjens, H. A. M., & van den Berg, J. W. (2007) · CHEST Journal · doi:10.1378/chest.07-0208 · Cited by 151
Moli, R. L., Baldeschi, L., Saeed, P., Regensburg, N. I., Mourits, M. P., & Wiersinga, W. M. (2007) · Thyroid · doi:10.1089/thy.2006.0267 · Cited by 136
Menconi, F., Marinò, M., Pinchera, A., Rocchi, R., Mazzi, B., Nardi, M., Bartalena, L., & Marcocci, C. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1800 · Cited by 132
Lai, A., Sassi, L., Compri, E., Marino, F., Sivelli, P., Piantanida, E., Tanda, M. L., & Bartalena, L. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2130 · Cited by 129
van Geest, R. J., Sasim, I. V., Koppeschaar, H. P. F., Kalmann, R., Stravers, S., Bijlsma, W. R., & Mourits, M. P. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0558 · Cited by 127
Glucocorticoids, lipocortins and the immune response
Goulding, N. J., & Guyre, P. M. (1993) · Current Opinion in Immunology · doi:10.1016/0952-7915(93)90089-b · Cited by 120
Marcocci, C., Bartalena, L., Panicucci, M., Marconcini, C., Cartei, F., Cavallacci, G., Laddaga, M., Campobasso, G., Baschieri, L., & Pinchera, A. (1987) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1987.tb00836.x · Cited by 119
Aktaran, Ş., Akarsu, E., Erbağcı, İ., Araz, M., Okumuş, S., & Kartal, M. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01004.x · Cited by 113
WEISSEL, M., & Hauff, W. (2000) · Thyroid · doi:10.1089/thy.2000.10.521 · Cited by 101
Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy.
Kendall-Taylor, P., Crombie, A. L., Stephenson, A. M., Hardwick, M., & Hall, K. (1988) · BMJ · doi:10.1136/bmj.297.6663.1574 · Cited by 94
High-dose intravenous corticosteroid therapy for Graves’ ophthalmopathy
Macchia, P. E., Bagattini, M., Lupoli, G., Vitale, M., Vitale, G., & Fenzi, G. (2001) · Journal of Endocrinological Investigation · doi:10.1007/bf03343835 · Cited by 94
Graves’ Orbitopathy Activation after Radioactive Iodine Therapy with and without Steroid Prophylaxis
Vannucchi, G., Campi, I., Covelli, D., Dazzi, D., Currò, N., Simonetta, S., Ratiglia, R., Beck-Peccoz, P., & Salvi, M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0506 · Cited by 92
Kauppinen‐Mäkelin, R., Karma, A., Leinonen, E. S., Löyttyniemi, E., Salonen, O. L. M., Sane, T., Setälä, K., Viikari, J., Heufelder, A. E., & Välimäki, M. J. (2002) · Acta Ophthalmologica Scandinavica · doi:10.1034/j.1600-0420.2002.800316.x · Cited by 92
Measuring disease activity to predict therapeutic outcome in Graves’ ophthalmopathy
Terwee, C. B., Prummel, M. F., Gerding, M. N., Kahaly, G. J., Dekker, F. W., & Wiersinga, W. M. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02186.x · Cited by 85
Self-citationA questionnaire survey on the management of Graves’ orbitopathy in Europe
_, _., Perros, P., Baldeschi, L., Boboridis, K. G., Dickinson, A. J., Hullo, A., Kahaly, G. J., Kendall-Taylor, P., Krassas, G. E., Lane, C., et al. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02201 · Cited by 76
Self-citationEffect of steroid pulse therapy with and without orbital radiotherapy on Graves’ ophthalmopathy
Ohtsuka, K., Sato, A., Kawaguchi, S., Hashimoto, M., & Suzuki, Y. (2003) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01970-0 · Cited by 69
Woltman, A. M., Massacrier, C., de Fijter, J. W., Caux, C., & van Kooten, C. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.12.6181 · Cited by 66
Hart, R. H., Kendall‐Taylor, P., Crombie, A. L., & Perros, P. (2005) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2005.21.328 · Cited by 56
Salvi, M., Vannucchi, G. M., Sbrozzi, F., de Castello, A. B., Carnevali, A., Fargion, S. R., & Beck‐Peccoz, P. (2004) · Thyroid · doi:10.1089/1050725041692927 · Cited by 51
Marinò, M., Morabito, E., Altea, M. A., Ambrogini, E., Oliveri, F., Brunetto, M. R., Pollina, L., Campani, D., Vitti, P., Bartalena, L., et al. (2005) · Journal of Endocrinological Investigation · doi:10.1007/bf03345386 · Cited by 48
Tehrani, M., Krummenauer, F., Mann, W. J., Pitz, S., Dick, H. B., & Kahaly, G. J. (2004) · European Journal of Ophthalmology · doi:10.1177/112067210401400302 · Cited by 41
Self-citationHigh-dose intravenous glucocorticoid therapy abrogates circulating dendritic cells
Suda, T., Chida, K., Matsuda, H., Hashizume, H., Ide, K., Yokomura, K., Suzuki, K., Kuwata, H., Miwa, S., Nakano, H., et al. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2003.09.028 · Cited by 39
High-Dose Intravenous Steroid Pulse Therapy in Thyroid-Associated Ophthalmopathy.
Tagami, T., Tanaka, K., Sugawa, H., Nakamura, H., Miyoshi, Y., Mori, T., & Nakao, K. (1996) · Endocrine Journal · doi:10.1507/endocrj.43.689 · Cited by 38
Gürsoy, A., Cesur, M., Erdoğan, M. F., Çorapçıoğlu, D., & Kamel, N. (2006) · Endocrine · doi:10.1385/endo:29:3:513 · Cited by 37
Lendorf, M. E., Rasmussen, Å. K., Fledelius, H. C., & Feldt‐Rasmussen, U. (2009) · Thyroid · doi:10.1089/thy.2009.0069 · Cited by 34
What to do for moderate‐to‐severe and active Graves’ orbitopathy if glucocorticoids fail?
Bartalena, L. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03783.x · Cited by 33
Kubota, S., Ohye, H., Nishihara, E., Kudo, T., Ito, M., Fukata, S., Amino, N., Kuma, K., & Miyauchi, A. (2005) · Endocrine Journal · doi:10.1507/endocrj.52.735 · Cited by 31
Janka-Junttila, M., Moilanen, E., Hasala, H., Zhang, X., Adcock, I. M., & Kankaanranta, H. (2006) · Journal of Inflammation · doi:10.1186/1476-9255-3-10 · Cited by 26
Lazarus, J. H., & Marinò, M. (2010) · KARGER eBooks · doi:10.1159/000320425 · Cited by 21
Ohtsuka, K. (2002) · Japanese Journal of Ophthalmology · doi:10.1016/s0021-5155(02)00544-0 · Cited by 20
Treatment of Thyroid Eye Disease
Phillips, M. E., Marzban, M. F., & Kathuria, S. S. (2010) · Current Treatment Options in Neurology · doi:10.1007/s11940-009-0054-0 · Cited by 19
Management of Moderately Severe Graves’Orbitopathy
Kahaly, G. J. (2007) · KARGER eBooks · doi:10.1159/000107455 · Cited by 17
Self-citationKulig, G., Andrysiak-Mamos, E., Sowińska-Przepiera, E., Kulig, J., Karakiewicz, B., Brodowski, J., Robaczyk, M. G., Homa, K., Letkiewicz, M., & Syrenicz, A. (2009) · PubMed · Cited by 17
Endokrine Orbitopathie – aktuelle Diagnostik und Therapie*
Ponto, K. A., & Kahaly, G. J. (2008) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-008-1112-1 · Cited by 15
Self-citationPharmacological Treatments for Thyroid Eye Disease
Modjtahedi, S. P., Modjtahedi, B. S., Mansury, A. M., Selva, D. N., Douglas, R. S., Goldberg, R. A., & Leibovitch, I. (2006) · Drugs · doi:10.2165/00003495-200666130-00003 · Cited by 15
Cited by
Smith, T. J., & Hegedüs, L. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1510030 · Cited by 1,257
Bartalena, L., Kahaly, G. J., Baldeschi, L., Dayan, C. M., Eckstein, A., Marcocci, C., Marinò, M., Vaidya, B., Wiersinga, W. M., _, _., et al. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0479 · Cited by 1,054
Self-citationBartalena, L., Baldeschi, L., Boboridis, K., Eckstein, A., Kahaly, G. J., Marcocci, C., Perros, P., Salvi, M., & Wiersinga, W. M. (2016) · European Thyroid Journal · doi:10.1159/000443828 · Cited by 943
Self-citationTeprotumumab for Thyroid-Associated Ophthalmopathy
Smith, T. J., Kahaly, G. J., Ezra, D. G., Fleming, J. C., Dailey, R. A., Tang, R. A., Harris, G. J., Antonelli, A., Salvi, M., Goldberg, R. A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614949 · Cited by 756
Self-citationTeprotumumab for the Treatment of Active Thyroid Eye Disease
Douglas, R. S., Kahaly, G. J., Patel, A., Sile, S., Thompson, E. H. Z., Perdok, R., Fleming, J. C., Fowler, B. T., Marcocci, C., Marinò, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910434 · Cited by 752
Self-citation
Metadata
- Authors
- Zang, S., Ponto, K. A., & Kahaly, G. J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-02
- Volume
- 96
- Issue
- 2
- Pages
- 320-332
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2052463348
- Cited by
- 379
- References
- 54
- FWCI
- 10.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.